Listen "IASLC - ASCO 2024 Summary--Part 1"
Episode Synopsis
Title: ASCO 2024 Highlights Part 1 - Plenary
Description: ASCO 2024 had so much lung cancer data, two podcast episodes are required to cover all the data presented. In this first episode, hosts Dr. Stephen Liu and Dr. Narjust Florez cover the LAURA trial, the ADAURA trial, the KRYSTAL-12 study, the phase III EVOKE-01 trial, the phase III ADRIATIC trial, and the REACH-PC trial.
Guest: Dr. David Spigel is the Chief Scientific Officer at Sarah Cannon Research Institute and recipient of the IASLC Heine H. Hansen Lectureship for SCLC.
Guest: Dr. Lecia Sequist is the Program Director for Cancer Early Detection & Diagnostics at Massachusetts General Cancer Center and the Landry Family Professor of Medicine in the Field of Medical Oncology at Harvard Medical School.
Description: ASCO 2024 had so much lung cancer data, two podcast episodes are required to cover all the data presented. In this first episode, hosts Dr. Stephen Liu and Dr. Narjust Florez cover the LAURA trial, the ADAURA trial, the KRYSTAL-12 study, the phase III EVOKE-01 trial, the phase III ADRIATIC trial, and the REACH-PC trial.
Guest: Dr. David Spigel is the Chief Scientific Officer at Sarah Cannon Research Institute and recipient of the IASLC Heine H. Hansen Lectureship for SCLC.
Guest: Dr. Lecia Sequist is the Program Director for Cancer Early Detection & Diagnostics at Massachusetts General Cancer Center and the Landry Family Professor of Medicine in the Field of Medical Oncology at Harvard Medical School.
More episodes of the podcast Lung Cancer Considered
LCC in Greek: WCLC 2025 Highlights
10/10/2025
LCC in Arabic: WCLC 2025 Highlights
03/10/2025
Lung Cancer Considered: Targeting EGFR NSCLC
03/10/2025
LCC in Korean: WCLC 2025 Highlights
30/09/2025
LCC in Portuguese: WCLC 2025 Highlights
16/09/2025